Japan is confident about the future of regenerative medicine

The Ministry of Economy, Trade and Industry of Japan (METI) on February 22 said Japan's renewable medicine market is expected to reach a total turnover of 1,600 billion yen in 2030, up from the scale. modest 26 billion yen in 2012 today.

Also according to METI, Japan's regenerative medicine market in 2030 will develop with specific products developed from human cells with various types and especially products from multi cell types. Artificial power may be commercialized in the future.

METI hopes that the ministry's assessment will encourage investment in the sector that brings these promising results.

The field of regenerative medicine caught the attention in Japan after Kyoto University professor Shinya Yamanaka won the Nobel Prize in Medicine last year with his groundbreaking research results on artificial multipurpose cells (iPS ) from which can produce any type of cell of the human body.

METI's assessment comes after the ministry takes into account the number of potential patients in Japan along with the per capita treatment costs. On a global scale, METI predicts that the regenerative medicine market will increase to 17,000 billion yen in 2030, far exceeding 340 billion yen in 2012.

METI also said that the cost of experimental treatments with regenerated medical products could be reduced by about 60% while the costs are reduced by 20% if Japan implements positive measures. such as reforming regulations to facilitate relevant agencies and authorities to quickly approve regenerated medical products in clinical trials, a process that now takes 7 year.

Regenerative medicine is the process of replacing or regenerating human cells, tissues and organs to restore or establish their normal functioning. This area promises the ability to regenerate tissues and organs in the body by replacing damaged tissues or stimulating the body's self-repair mechanism to heal incapacitated tissues and organs. fix yourself earlier.

Regenerative medicine also helps scientists nourish laboratory tissues and organs and implant safely when the human body cannot repair itself. What is especially important is that regenerative medicine is also capable of resolving the problem when the number of donated organs is insufficient to meet the needs of patients who need transplants. In addition, regenerative medicine will thoroughly address the risk of post-transplant rejection if the organs of internal organs are taken from the patient's own tissue or cells.